U.S. Markets open in 9 hrs 21 mins

Pacific Biosciences of California, Inc. (PACB)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
3.33+0.10 (+3.10%)
At close: 4:00PM EDT
People also watch
FLDMILMNFOLDGHDXPGNX
  • My best guess here with these director buys is that Roche has won the battle on pps and will take them for ~$8. Someone mentioned Roche did the same thing to IGEN, although IGEN eventually got the price they asked for as Roche was caught illegally shorting their stock. What a joke.
  • Could it be that the whisper numbers are out???
  • Well fellow investors, I've seen some pretty dead door nails over the years
    but I think PACB is making all those dark rusty nails look like shiny bundles of life.
    Such is the power of PACB!
  • Is this the day it dips below 3? Not to worry though , pacb has the great hunkapillar leading the way. Plus, focusing on ants and yeast will be the impetus to drive this stock to 20. If it doesnt go below 3 today or in the next few days, I see nothing to prevent it from falling below that number when earnings are announced. Yes, the great hunkapillar will speak . He speaks 4x a year so be sure not to miss it!
  • http://www.conferencecalltranscripts.org/4/summary2/?id=3980702

    Conference Call Transcripts
    Company Conference Call Transcripts
    www.conferencecalltranscripts.org
  • Novogene and Pacific Biosciences to Jointly Develop and Co-Market Novel Applications Based on Sequel Platform

    SAN DIEGO and MENLO PARK, Calif., July 18, 2017 (GLOBE NEWSWIRE) -- Novogene, a leading global provider of genomic services and solutions, and Pacific Biosciences of California, Inc. (NASDAQ:PACB), the leader in long-read sequencing, have agreed to jointly develop and promote novel applications based on the PacBio® Sequel® System. New applications developed under this agreement are expected to focus on basic and translational research in the field of precision medicine, including methods for sample processing, workflow automation, algorithm development, and database construction.
    novogene logo (3).jpg

    Sequel Systems are based on Single Molecule, Real-Time (SMRT®) technology, which has the advantage of uniform coverage across all genome regions, including palindromes and low-diversity regions of the genome. Genome sequencing with PacBio Systems helps provide more complete and accurate views of all types of genomic variation, revealing SNPs/SNVs, structural variants, mobile elements, haplotypes, epigenetics, and variants in low-complexity regions. Furthermore, the isoform sequencing (Iso-Seq®) method with the Sequel System generates full-length cDNA sequences, which can be used to profile the full complexity of the human transcriptome and discover novel genes, isoforms, and gene fusion events.

    With the ability to run up to 10 PacBio Sequel Systems, Novogene operates in a facility that has the largest capacity for SMRT Sequencing in a single location. As a leading genomic service provider with a comprehensive portfolio of service products, Novogene has extensive expertise in developing and marketing high-quality end-to-end service solutions, from sample preparation to data analysis and interpretation, for a variety of applications in diverse research and clinical fields.

    About Novogene Corporation

    Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and one of the largest sequencing capacities in the world. Novogene pursues scientific excellence, strong commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly developing world of genomics. With 1,800 employees, multiple locations around the world, 49 NGS related patents, and over 250 publications in top tier journal such as Nature and Science, Novogene has rapidly become a world-leader in NGS services. For more information, visit https://en.novogene.com/.

    About Pacific Biosciences

    Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences' products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences' technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.

    Forward-Looking Statements

    All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to future uses, quality, performance or advantages of, or benefits of using, products or technologies, future development or promotional efforts, the expected benefits of the company's collaboration with Novogene, the suitability of the company's products for particular markets or applications and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences' control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences' most recent filings with the Securities and Exchange Commission, including Pacific Biosciences' most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption "Risk Factors."

    Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

    Contacts:

    For Novogene:

    Joyce Peng, Ph.D.

    Global Marketing Director and General Manager

    San Diego, California

  • Looks like PACB is resorting to Fake news to pump up stock. Doesn't seem like anyone is buying it. :)
  • Even more news on Novogene website that wasn't published here-

    https://en.novogene.com/novogene-will-use-pacific-biosciences-smrt-technology-to-build-novo-disease-sv-genomes-database/

    Novogene Will Use Pacific Biosciences SMRT Technology to Build Novo-Disease SV Genomes Database - Novogene
    –First database of long-read whole genome sequencing data– San Diego, July 18, 2017 — Novogene announced today it plans to use Pacific Biosciences SMRT® technology to build a comprehensive Chinese genome database, Novo-Disease SV Genomes. The databas
    en.novogene.com
  • They need new leadership. this company has nothing to report. leadership needs to be ousted.
  • KTOV = Mcap $16 Mil /Cash $17 Mil / O/S 10.6 M / NDA submission for potential Blockbuster this Quarter = 20++BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension
    https://baystreet.ca/articles/research_reports/lifesci/Kitov062717.pdf

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets

    Products

    Kitov’s current pipeline products, KIT-301 and KIT-302, are combination drugs that treat OA pain and HTN simultaneously. In December 2015, KIT-302 successfully achieved the primary efficacy endpoint for its Phase III clinical trial. In August 2016, the United States Patent Office issued a patent covering KIT-302.

    Market

    Of the 27 million Americans with OA, 50% also suffer from HTN, which is also a common side effect of stand-alone OA drugs. With no single medication currently treating both conditions, KIT-301 and KIT-302 are targeting this multi-billion dollar market.

  • This is a very bad sign for PACB. They are trying to sell as much as they can before earning. If earning was decent they would inflate prices until after financial.
  • Obviously they are having trouble ridding the 15 million shares.
  • I don't think that this is such great news.
    1.) They are mainland Chinese. (Looking for a buyout at cheap prices),
    2.) They are a private company, with little to bring to the table. (Looking for a buyout at cheap, cheap prices).
    3.) At 3.5% up for today, the market ALSO doesn't really think that this is such big news. (They are looking for a buyout at cheap, cheap, CHEAP prices).
    4.) Past team-ups which I have seen with Chinese and US genomic companies DID NOT work out well for US shareholders.

    The reality is that they (Chinese) want something of great value for next to no cost. Doesn't usually end up well for US shareholders.

    I am kind of sickened by this past 6 months from PACB. All of it's potential and it's going to be handed over to a private, Chinese, military shell company for peanuts?

    I think that PACB management MUST be smoking something.
    WHERE is the rest of the scientific, and pharma world that is supposedly drooling over The Sequel and it's capabilities?
    Really? We're just supposed to give it away to the Red Mainland and be excited about it?
    Can we get a re-count on this? Pathetic..........
  • More developments in precision medicine with the Sequel from PACB website:

    Stanford Scientists Report First Use of PacBio Whole Genome Sequencing to Identify a Disease-Causing Mutation

    http://www.pacb.com/blog/stanford-scientists-report-first-use-pacbio-whole-genome-sequencing-identify-disease-causing-mutation/

  • If they don't resease new chemistry in next 6 to 8 weeks, we are all in deep trouble.
  • Could it be that the Chinese will be first movers in precision medicine before western companies? This article seems to indicate that investment in precision medicine is still a long way off. Thoughts?

    https://www.technologyreview.com/s/601883/the-white-house-is-pushing-precision-medicine-but-it-wont-happen-for-years/

  • Looks like PACB will go down the next few days. They must shed those shares in the public offering. Jacking prices up and slowly selling it down to 3.10 will not work this time. No one is buying.
  • Anyone else but me noticing the intraday spikes in the past few days or so? Feels calculated.. not sure what's up.
  • Population Genomics Study Shows Faster Evolution in Domesticated Yeast
    Tuesday, July 11, 2017

    Photo from Rising Damp (Flickr)
    In a Nature Genetics paper, scientists used SMRT Sequencing to detect and compare structural variations in several yeast strains in order to understand evolutionary genome dynamics. They found different rates of evolution among domesticated and wild strains, and suggest that “the influence of human activities” could explain this.

    “Contrasting evolutionary genome dynamics between domesticated and wild yeasts” comes from lead author Jia-Xing Yue, senior author Gianni Liti, and collaborators at the Université Côte d’Azur, the Wellcome Trust Sanger Institute, and other institutes. Choosing long reads to facilitate accurate detection of structural variants, they used PacBio sequencing and generated “end-to-end genome assemblies for 12 strains representing major subpopulations of the partially domesticated yeast Saccharomyces cerevisiae and its wild relative Saccharomyces paradoxus,” the scientists report. “The raw PacBio de novo assemblies of both nuclear and mitochondrial genomes showed compelling completeness and accuracy, with most chromosomes assembled into single contigs, and highly complex regions accurately assembled.”

    According to the team, the final 12 assemblies provided “unprecedented resolution” for analyzing subtelomeric regions, which yielded a detailed look at evolutionary genome dynamics. “In chromosomal cores, S. paradoxus shows faster accumulation of balanced rearrangements (inversions, reciprocal translocations and transpositions), whereas S. cerevisiae accumulates unbalanced rearrangements (novel insertions, deletions and duplications) more rapidly,” the scientists write. “In subtelomeres, both species show extensive interchromosomal reshuffling, with a higher tempo in S. cerevisiae.” The accelerated evolution in baker’s yeast is likely to be at least partly a function of human activity and the human-associated environments to which the organisms have been exposed, they add.

    The authors note that this study is an indicator of the utility of SMRT Sequencing for population genomics. Ultimately, they say, their results offer an intriguing new explanation for “why S. cerevisiae, but not its wild relative, is one of our most biotechnologically important organisms.”
  • its over!